Trimodality treatment in Stage III nonsmall cell lung carcinoma

In a trimodality treatment approach for Stage III nonsmall cell lung carcinoma (NSCLC), the prognostic impact of the ras mutation status in resection specimens was evaluated.

[1]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[2]  G. Scagliotti,et al.  Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer. , 2003, The oncologist.

[3]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Pignon,et al.  Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. R. Bishop,et al.  A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.

[6]  C. Bowden,et al.  Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Rübe,et al.  Chemotherapy (CT) and twice daily radio-chemotherapy (HA RT/CT) versus chemotherapy (CT) alone before surgery in stage III non small cell lung cancer (NSCLC): analysis of toxicity of a randomized trial , 1999 .

[8]  N. Willich,et al.  Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Junker.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy, A significant prognostic factor , 1998, Journal of Cancer Research and Clinical Oncology.

[10]  V. Budach,et al.  Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[12]  J. Roh,et al.  Correlation between K‐ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma , 1997, Cancer.

[13]  N. Choi,et al.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. V. van't Veer,et al.  Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Sugimachi,et al.  K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. , 1997, British Journal of Cancer.

[16]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[17]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Rom,et al.  Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. , 1995, Cancer research.

[19]  H. Novotná,et al.  Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  A. Syvänen.  Detection of point mutations in human genes by the solid-phase minisequencing method. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[21]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[22]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[23]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[24]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[25]  C. Marshall,et al.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. , 1991, Cancer research.

[26]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[27]  M. Sklar.  Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. , 1988, Cancer research.

[28]  M. Sklar.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.

[29]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[30]  M. Barbacid.  ras genes. , 1987, Annual review of biochemistry.

[31]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  D.,et al.  Regression Models and Life-Tables , 2022 .